Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Bernhard Frankenberger"'
Autor:
Daniela N. Männel, Olaf Ortmann, Arabel Vollmann-Zwerenz, Judith Eckl, Bernhard Frankenberger, Wolfgang Ernst, Anja K. Wege, Alexander Kroemer, Gero Brockhoff
Publikováno v:
International Journal of Cancer; Vol 129
Int. J. Cancer 129, 2194-2206 (2011)
International Journal of Cancer
Int. J. Cancer 129, 2194-2206 (2011)
International Journal of Cancer
The immunological impact on antibody-based anticancer therapies remains incompletely understood due to the lack of appropriate animal models for in vivo analysis. Here, we present a novel humanized tumor mouse (HTM) model, generated by concurrent tra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35694d37562bd80a35ab83322d3d5dd5
https://doi.org/10.1002/ijc.26159
https://doi.org/10.1002/ijc.26159
Autor:
Susanne Wilde, Barbara Mosetter, Dolores J. Schendel, Christiane Geiger, Maja Bürdek, Miran Javorovic, Bernhard Frankenberger, Stefani Spranger, Stefanie Tippmer, Iris Bigalke
Publikováno v:
The Journal of Immunology. 185:738-747
In this paper, we describe a new method for preparation of human dendritic cells (DCs) that secrete bioactive IL-12(p70) using synthetic immunostimulatory compounds as TLR7/8 agonists. Monocyte-derived DCs were generated using a procedure that provid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51c6917a215075851bbed94ea276a7b4
https://doi.org/10.4049/jimmunol.1000060
https://doi.org/10.4049/jimmunol.1000060
Autor:
Gerald Willimsky, Heike Pohla, Michael Siebels, Ronald Frank, Antonio Pezzutto, Dolores J. Schendel, Christian G. Stief, Ralph Oberneder, Bernhard Frankenberger, Alexander Buchner, Andrea Baur-Melnyk, Alfons Hofstetter, Joachim Kopp, Thomas Blankenstein
Publikováno v:
Human Gene Therapy. 21:285-297
Preclinical studies showed that the allogeneic tumor cell line RCC-26 displayed natural immunogenic potential that was enhanced through expression of CD80 costimulatory molecules and secretion of interleukin-2. Here we report the study of RCC-26/CD80
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e10e5fd097152868fe3824ae14b64acf
https://doi.org/10.1089/hum.2008.192
https://doi.org/10.1089/hum.2008.192
Autor:
Christine S. Falk, Bernhard Frankenberger, Dolores J. Schendel, Heike Pohla, Christiane Geiger, Elfriede Nößner
Publikováno v:
J. Mol. Med. 87, 595-612 (2009)
The development of immunotherapies for renal cell carcinoma (RCC) has been the subject of research for several decades. In addition to cytokine therapy, the benefit of various adoptive cell therapies has again come into focus in the past several year
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d3e3b8844c8664229ee2a033696171e
https://doi.org/10.1007/s00109-009-0455-2
https://doi.org/10.1007/s00109-009-0455-2
Autor:
Elfriede Nöner, Ralph Mocikat, Martin Dreyling, Bernhard Frankenberger, Ulrich Wahl, Michael Hallek, Konrad Kronenberger
Publikováno v:
Journal of Immunotherapy. 31:723-730
B cell-derived chronic lymphocytic leukemia (CLL) is an incurable disease that requires innovative therapeutic regimens. Experimental approaches of immunotherapy aiming at induction of systemic T-cell responses have been developed. Trioma cells provi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8244cc4e6b0d30370a797dad6cf7e404
https://doi.org/10.1097/cji.0b013e318183af26
https://doi.org/10.1097/cji.0b013e318183af26
Autor:
Martin Röcken, Elfriede Nößner, Carolin Lüking, Konrad Kronenberger, Ralph Mocikat, Bernhard Frankenberger
Publikováno v:
International Journal of Cancer. 122:2280-2285
Tumor-specific T cells are crucial for immunologic control of malignant disease. T cells can be induced in vivo by vaccination or adoptively transferred after activation ex vivo. We investigated the requirements for generating T cells with optimal an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca19dc82e53e38bfec08d75f01333c4
https://doi.org/10.1002/ijc.23393
https://doi.org/10.1002/ijc.23393
Publikováno v:
Seminars in Cancer Biology. 17:330-343
The clear evidence that tumor-infiltrating lymphocytes with anti-tumor activity exist in situ raises the question why renal cell carcinomas (RCCs) progress in vivo. A complex array of factors and pathways has been identified that impinges on innate a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f2fec366d2bdbf7ada3dd59e69f10b1
https://doi.org/10.1016/j.semcancer.2007.06.004
https://doi.org/10.1016/j.semcancer.2007.06.004
Publikováno v:
Mol. Ther. 12, 734-743 (2005)
Previous studies have analyzed transfer of RNA-encoded tumor-associated antigens (TAAs) into immature dendritic cells (DCs) because of their exceptional ability to internalize antigens. Concerns have been raised regarding the use of immature DCs in c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af4ea7ecd2bdee564a6f45bd42b2f745
Autor:
Dolores J. Schendel, Birgit Stadlbauer, B Dörken, Gerald Willimsky, Ralph Oberneder, Bernhard Frankenberger, Alfons Hofstetter, Heike Pohla, Antonio Pezzutto, Thomas Blankenstein
Publikováno v:
Bone Marrow Transplantation. 25:S83-S87
An allogeneic tumor cell vaccine should display a natural immunogenicity that allows the stimulation of tumor-reactive effector cells in patients. Furthermore, the vaccine should express antigens that are shared by many tumors to which patients are n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8c03969b3a1b16e7afdcc44ef6159df
https://doi.org/10.1038/sj.bmt.1702362
https://doi.org/10.1038/sj.bmt.1702362
Publikováno v:
Oncoimmunology
The clinical use of lymphocytes engineered to express high affinity T-cell receptors (TCRs) specific for two broadly expressed tumor-associated antigens is strongly limited by MHC-restricted fratricide of lymphocytes and TCR-mediated killing of hemat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b6ff7a8a15d263e9eff12611890626b
http://europepmc.org/articles/PMC3583918
http://europepmc.org/articles/PMC3583918